Table 2.

Summary of EMT markers expressed in NSCLC cell lines in vitro

NSCLC cell lineCell typeErlotinib sensitivityE-cadherinP-cadherinγ-cateninN-cadherinVimentinFibronectin
H292MucoepedermoidSensitive+++
H322AdenoSensitive+++
H358AdenoSensitive+++
H441AdenoSensitive+++
Calu3AdenoSensitive++
A427Lung carcinomaSensitive+++
A549AdenoIntermediate+++
Colo699AdenoIntermediate++
H2122AdenoIntermediate+
H1703SquamousInsensitive+
Sw1573SquamousInsensitive++
H460Large cellInsensitive++
Calu6Lung cancerInsensitive++
H1437AdenoInsensitive++
H1299Large cellInsensitive++
Hop92Large cellInsensitivend++
H23AdenoInsensitivend+
  • NOTE: Expression of the individual proteins was determined by immunoblot analysis ( Fig. 2B and C and data not shown). Those cell lines most sensitive to growth inhibition in vitro and in xenografts by erlotinib expressed the epithelial markers E-cadherin, P-cadherin, and β-catenin. Cell lines less sensitive to erlotinib have lost expression of E- and P-cadherin and gained expression of the mesenchymal proteins vimentin and fibronectin. The majority of cell lines also retained expression of cytokeratins 8 and/or 18, with the exception of H1703.